Dapagliflozin and Right Heart Function After Off-Pump Heart Bypass Surgery
Observes dapagliflozin's effect on right heart function after bypass surgery in 72 patients.
Key facts
- Who runs it
- Pyatigorsk City Clinical Hospital Number 1
- Where
- Pyatigorsk, RussiaSee the site
- Trial code
- Registry title
- Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting
- Status
- Recruiting
- People taking part
- 72 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 1 Jul 2028
- Type of study
- Observational
- Record updated
- 17 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a weakened heart pump (LVEF below 50%) who are having planned off-pump coronary artery bypass surgery alone.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Left ventricular ejection fraction (LVEF) below 50% on the heart scan before surgery; planned (elective) bypass surgery on a beating heart (off-pump).
- Earlier treatment
- No earlier bypass surgery or other heart surgery.
Main reasons for not taking part
- Valve surgery at the same time
- Emergency or urgent bypass surgery
- Heart attack around the time of surgery, or cardiogenic shock
- Severe chronic kidney disease (eGFR below 25 mL/min/1.73 m²)
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥ 18 years
- Elective isolated off-pump coronary artery bypass grafting (OPCAB)
- Left ventricular ejection fraction (LVEF) < 50% documented on pre-operative echocardiography
- Written informed consent
Who cannot take part
- Concomitant valve surgery
- Conversion to on-pump during surgery
- Previous CABG or any prior cardiac surgery
- Contraindication to SGLT2 inhibitors
- Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI)
- More than moderate valvular heart disease
- Severe chronic kidney disease (eGFR < 25 mL/min/1.73 m²)
- Emergency or urgent CABG
- Cardiogenic shock
- Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination)
- Inability to obtain adequate echocardiographic windows
- Pregnancy or breastfeeding
Where in Russia
- Pyatigorsk City Clinical Hospital Number 1Pyatigorsk, RussiaContact: Samson S. Badalyan, MD, PhDTaking people
About the trial
What the trial wants to find out
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction <50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).
The group in the trial
- Dapagliflozin Group
Patients receiving dapagliflozin 10 mg once daily starting at 1 month after off-pump CABG
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Artery Bypass Grafting: a Prospective Single-Center Study
- Plain-language title
- Dapagliflozin and Right Heart Function After Off-Pump Heart Bypass SurgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 June 2026